What Is the KLOW Blend? GHK-Cu, KPV, BPC-157 & TB-500

The rationale is that the four peptides cover different stages of healing: lowering inflammation (KPV), supplying blood flow and growth signals (BPC-157), moving repair cells into place (TB-500), and rebuilding collagen (GHK-Cu).

GHK-Cu. First identified in human plasma in 1973 by Loren Pickart. Its levels fall with age. Lab and small human studies show topical GHK-Cu can improve skin firmness and wrinkles, and animal studies show faster wound healing. Evidence for injected GHK-Cu in people is very limited.

KPV. In mouse models of colitis, KPV taken orally or delivered in nanoparticles reduced gut inflammation. It has not been tested in human trials.

BPC-157 and TB-500. Both have extensive animal data for tissue repair but very limited human data. See our BPC-157 and TB-500 guides for details.

The combination. There are no studies of KLOW or any four-peptide combination like it.

There is no human safety data for KLOW. Four peptides in one vial means four sets of unknowns, and it becomes harder to tell which ingredient causes a reaction. GHK-Cu adds copper, and injected GHK-Cu has been linked to injection-site irritation. As with Wolverine, BPC-157 and TB-500 promote blood vessel growth, which raises theoretical concerns in people with cancer. BPC-157 and TB-500 are banned in sport by WADA.

No. None of the four peptides is FDA-approved for injection, and there is no approved blend.

In April 2026, the FDA removed BPC-157, TB-500, KPV and several other peptides from its “Category 2” list of compounding ingredients with significant safety concerns. In July 2026, the FDA’s Pharmacy Compounding Advisory Committee voted narrowly (8–6) to recommend adding BPC-157, TB-500 and KPV to the 503A Bulks List. That vote is advisory only. As of October 2026, the FDA has not added them to the list, so they still cannot be legally compounded, and none is an approved drug.

GHK-Cu was also removed from Category 2 in April 2026 after its nomination was withdrawn. The FDA plans to consult its advisory committee on injectable GHK-Cu by early 2027. Topical GHK-Cu remains widely used in cosmetics.

KLOW vs GLOW. The only difference is KPV. KLOW is marketed toward people interested in inflammation and gut-related research, while GLOW is aimed at skin and tissue repair.

KLOW vs Wolverine. Wolverine is the simplest of the three, with just BPC-157 and TB-500. KLOW adds two more peptides, which means more to verify on each COA.

Products sold as KLOW by research suppliers are laboratory chemicals, not medicines. They are not made under drug manufacturing rules, so quality varies a lot between vendors. If you are evaluating a KLOW supplier for lab research, these are the checks that matter:

• Batch-specific COA: the certificate should match the lot number on your vial, not a generic sample.
• Independent lab: testing should come from a named third-party lab, ideally with a way to verify the report online.
• Identity, not just purity: HPLC purity alone does not confirm the right molecule; look for mass spectrometry (MS) identity confirmation.
• Endotoxin and sterility results: these matter for any injectable research material.
• Correct fill amount: the measured content should be close to the labeled milligrams.

Our Trusted Sources page lists vendors we track, with current community codes. Our guide to reading a certificate of analysis explains each line of a COA.

• KLOW is a supplier blend of GHK-Cu, KPV, BPC-157 and TB-500.
• It is GLOW plus the anti-inflammatory peptide KPV.
• Each ingredient has mostly animal or lab evidence; the blend has none.
• None of the four is FDA-approved for injection, and the FDA has not acted on the 2026 advisory vote.
• A blend’s COA should confirm the identity and amount of every peptide.

What is the KLOW peptide blend?

KLOW is a research supplier blend of four peptides: GHK-Cu, KPV, BPC-157 and TB-500.

What is the difference between KLOW and GLOW?

KLOW adds KPV, an anti-inflammatory tripeptide, to the GLOW blend of GHK-Cu, BPC-157 and TB-500.

Is KLOW FDA-approved?

No. None of its four peptides is FDA-approved for injection, and there is no approved blend.

Has KLOW been studied?

No. Each ingredient has its own research, mostly in animals or lab studies, but the four-peptide combination has never been tested.

What does KPV do?

KPV is a 3-amino-acid fragment of α-MSH that reduced gut inflammation in mouse models of colitis. It has not been tested in human trials.

• Pickart & Margolina (2018), International Journal of Molecular Sciences – Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data
• Dalmasso et al. (2008), Gastroenterology – PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation
• FDA – Pharmacy Compounding Advisory Committee meeting, July 23–24, 2026
• FDA – Interim 503A Bulks List update (April 2026)